[Paper] survodutide MASH data is the most interesting hepatic readout in the class
Trying to settle this properly because the thread from last year went in circles. The claim: MASH matters. The counter-claim: it is measurement error. Both sides have been asserting it confidently for about 3 months without either producing anything. What would actually settle it is 9 people measuring the same thing…
MASH claims need the trial and the biopsy endpoint
Not convinced. The evidence does not support that reading.
MASH claims need the trial and the biopsy endpoint
I am going to push back on this slightly.
the safety profile is not just tirzepatide amplified
glucagon injection is a different vector than GLP-1
phase 20 data is interesting, phase 12 will be different